In clinical studies, a CD19/CD3 molecule built on this platform, blinatumomab, has shown very high efficacy in adults with relapsed or refractory CD19+ acute lymphoblastic leukemia, highlighting the therapeutic value of BiTE antibodies.5, 6, 7 A CD33/CD3 molecule, AMG 330, is currently in preclinical development for the treatment of acute myeloid leukemia (AML). Here, CD33 is linked to acute myeloid leukemia.